Investor Overview

Hemostemix is on track to becoming the first company to commercialize an autologous cell therapy for critical limb ischemia.

Download Corporate Presentation Aug-2018

Stock Info

HEM
TSX-V
0.105
0.000
Data as of
Minimum 20 minute delay